Compare EZGO & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZGO | VIVS |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.1M |
| IPO Year | 2020 | 2010 |
| Metric | EZGO | VIVS |
|---|---|---|
| Price | $0.77 | $0.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 58.7K | ★ 721.4K |
| Earning Date | 08-14-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,603,000.00 |
| Revenue This Year | N/A | $228,144.28 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.82 |
| 52 Week Low | $0.01 | $0.14 |
| 52 Week High | $3.30 | $3.40 |
| Indicator | EZGO | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 35.20 |
| Support Level | $0.73 | N/A |
| Resistance Level | $1.28 | $0.30 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 27.52 | 23.81 |
EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.